Werewolf Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the and

Condensed Consolidated Statements of Operations (unaudited)

(amounts in thousands, except share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2024	2023	2024	2023
Revenue:
Collaboration revenue	$1,143	$8,081	$1,885	$12,545
Operating expenses:
Research and development	15,271	9,583	28,179	21,289
General and administrative	4,832	4,565	9,828	9,546
Total operating expenses	20,103	14,148	38,007	30,835
Operating loss	(18,960)	(6,067)	(36,122)	(18,290)
Other income:
Interest income	1,793	1,949	3,766	3,467
Interest expense	(1,142)	(955)	(2,145)	(1,126)
Loss on extinguishment of debt	(553)	—	(553)	—
Other income (expense), net	1,613	(25)	1,612	(1,131)
Total other income	1,711	969	2,680	1,210
Net loss	$(17,249)	$(5,098)	$(33,442)	$(17,080)
Net loss per common share, basic	$(0.40)	$(0.14)	$(0.79)	$(0.49)
Net loss per common share, diluted	$(0.43)	$(0.14)	$(0.82)	$(0.49)
Weighted-average common shares outstanding, basic	43,521,406	35,557,701	42,564,342	35,173,327
Weighted-average common shares outstanding, diluted	44,043,184	35,557,701	42,825,231	35,173,327

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.